focus -WSS

focus

author：comprehensive 2025-09-02 13:41:52 - browse：6363

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： Adam's Biotech Scorecard: Do Sarepta's exon

WSS

Divers poised to search for children washed away in Pennsylvania flash flood

Childbirth

Indian pharmaceutical industry in denial over drug

Lab trade group sues FDA to halt regulation of lab

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

explore

focus

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Heart attack and stroke risk calculators need revising

Focused ultrasound for uterine fibroids: an uphill battle

Duchenne breakthrough therapy leaves behind pioneering families

Indian pharmaceutical industry in denial over drug

Apple is now the first public company to be valued at $3 trillion

I learned firsthand about improving diversity in clinical trials

Medical leaders decry Supreme Court decision on affirmative action

Indian pharmaceutical industry in denial over drug

explore

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

David Sabatini, ex

Why Congress must ban federal programs from using QALYs

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Tocagen's brain cancer gene therapy trial continues. Investors worry

First Opinion Podcast: What happens when kids become caregivers?

Wikipedia

Wikipedia

leisure time

Wikipedia